|
Published by: Kalorama Information
Published: Apr. 1, 2001 - 755 Pages This package consists of two reports and is a 10% savings over buying the reports separately.
Table of Contents
Current Developments in Immunotherapy Markets and Technology
Chapter One
Executive Summary
- Introduction
- Scope And Methodology
- Size And Growth Of Market
- Market Trends
- The Nature Of The Industry
- The Applications
- Cancer
- Rheumatoid Arthritis
- Hiv/Aids
- Autoimmune Diseases
- Allergy And Asthma
- Vaccines
Chapter Two
Introduction
- Background
- Defining Immunotherapy
- The Pros And Cons Of Immunotherapy
- Point Of View
Chapter Three
Cancer Immunotherapy
- Epidemiology
- Market Population Trends
- Cancer Prevalence Trends
- Cancer Incidence Trends
- Immunological And Vaccine Approaches
- Market Overview
- Immunotherapy Background
- The Technological Basis For Cancer Immunotherapy
- Cytokine Therapeutics
- Genetic Cytokine Stimulation
- Cancer Vaccines
- Modified Antibodies
- Alternative Approaches To Cancer Immunotherapy
- Progress In Cancer Immunotherapy
- Limitations Of Immune Therapy
- The Commercial Outlook
Chapter Four
Rheumatoid Arthritis
- Background And Epidemiology
- Market Overview
- Immunotherapy Approaches
- Commercial Outlook
Chapter Five
Hiv/Aids
- Background And Epidemiology
- Market Overview
- Immunotherapy Approaches
- Commercial Outlook
Chapter Six
Autoimmune Diseases
- Background And Epidemiology
- Multiple Sclerosis Myasthenia Gravis
- Scleroderma
- Systemic Lupus Erythematosus
- Market Overview
- Immunotherapy Approaches
- Commercial Outlook
Chapter Seven
Allergy And Asthma
- Background And Epidemiology
- Market Overview
- Immunotherapy Approaches
- Commercial Outlook
Chapter Eight
Vaccines
- Background And Epidemiology
- Market Overview
- Immunotherapy Approaches
- Commercial Outlook
Chapter Nine
Company Profiles
- Abgenix, Inc.
- Amgen, Inc.
- Argonex, Inc.
- Autoimmune, Inc.
- Biogen, Inc.
- Biomira, Inc.
- Centocor (Johnson & Johnson)
- Corixa Corp.
- Cypress Bioscience, Inc.
- Genzyme Molecular Oncology
- Igeneon Gmbh
- Immunex, Inc.
- Morphosys Ag
- Vasogen, Inc.
- Vertex Pharmaceuticals, Inc.
- Vical, Inc.
Chapter Ten
Conclusions And Strategic Implications
Appendix A: Glossary
Appendix B: Company Names and Addresses
Advances in Cancer Therapy
Executive Summary
Introduction
Scope And Methodology
Size And Growth Of The Market
Market Trends
The Nature Of The Industry
The New Technologies
Chapter Two
Introduction
- What Is Cancer?
- Who Gets Cancer?
Point Of View
Chapter Three
Cancer Epidemiology
Market Population Trends
- Variations In Global Cancer Incidence
Cancer Prevalence Trends
Cancer Incidence Trends
Chapter Four
Cancer Therapy Markets
Market Overview
- Antineoplastic Drugs
- Cytotoxic Drugs
- Hormonal Drugs
- Adjunctive/Side-Effect Management Drugs
- Hematopoietic Restoration
- Severe Pain Management
- Opportunistic Infection Control
- International Market Overview
Chapter Five
- Current Therapeutic Approaches And Technology
- How Cancer Is Treated
- Sur
- Laser Surgery
- Electrosurgery
- Cryosurgery
- Radiation Therapy (Radiotherapy
- External Radiation Therapy
- Internal Radiation Therapy
- Chemotherapy
- Hormone Therapy
- Biological Therapy
Chapter Six
- Advanced Cancer Therapeutics And The New Paradigm
- The New Paradigm
- Emerging Approaches To Cancer Therapy And Management: An Overview
Chapter Seven
- Immunological And Vaccine Approaches
- The Technological Basis For Cancer Immunotherapy
- Cytokine Therapeutics
- Genetic Cytokine Stimulation
- Cancer Vaccines
- Modified Antibodies
- Alternative Approaches To Cancer Immunotherapy
- Progress In Cancer Immunotherapy
- Limitations Of Immune Therapy
- The Commercial Outlook
Chapter Eight
- Antiproliferative Approaches
- Angiogenesis Regulators
- Angiogenic Regulators In Tumor Vascularization
- Progress In Angiogenesis Inhibitor Development
- The Commercial Outlook
Chapter Nine
- Photodynamic Therapy
- Mechanism Of Action
- Photosensitizers
- The Benefits And Limitations Of Pdt
- Applications Of Pdt In Cancer
- The Commercial Outlook
Chapter Ten
- Gene Therapy Approaches
- Gene Therapy: Barriers And Drivers
- The Technology Of Gene Therapy
- Physical Gene Insertion Approaches
- Direct Injection Of Genetic Material
- Microprojectile Injection
- Electroporation
- Lithotriptic Shock Wave Insertion
- Chemical Gene Insertion Approaches
- Chemical Transfection
- Lipofection
- Cytofection
- Liposomal Transfer
- Biological Gene Insertion Approaches
- Retrovirus Gene Vectors
- Adenoviral Gene Vectors
- Adeno-Associated Viruses (Aavs)
- Herpesvirus Gene Vectors (Hsv-1)
- Other Biological Vectors
- Artificial Chromosome Gene Vectors
- Ligand/Receptor Gene Vectors
- Types And Effects Of Therapeutic Genes
- Phenotype Alteration With Tumor Suppressor Genes
- Phenotype Alteration With Oncogenes
- Induction/Reduction Of Multidrug Resistance
- Induction Of Cellular Toxicity By Gene Transfer
- The Last Word In Gene Therapy
- The Commercial Outlook
Chapter Eleven
- Cell Cycle And Apoptosis Approaches
- Apoptosis
- Inducing Apoptosis In Tumors
- Cell Cycle-Based Cancer Therapeutics
- The Commercial Outlook
Chapter Twelve
- Company Profiles
- Abgenix, Inc.
- Agouron Pharmaceuticals, Inc
- Amgen, Inc.
- Biomira, Inc.
- Bristol-Myers Squibb Co.
- British Biotech Plc
- Collagenex Pharmaceutics, Inc.
- Corixa, Corp.
- Dusa Pharmaceuticals, Inc.
- Genta, Inc.
- Genzyme Molecular Oncology
- Isis Pharmaceuticals, Inc.
- Morphosys Ag
- Onxy Pharmaceuticals, Inc
- Pharmacyclics, Inc
- Ribozyme Pharmaceuticals, Inc
- Sugen, Inc
- Vical, Inc.
- Competitive Summary
Chapter Thirteen
- Conclusions And Strategic Implications
- First Conclusion
- Implications
- Second Conclusion
- Implications
- Third Conclusion
- Implications
- Fourth Conclusion
- Implications
- Fifth Conclusion
- Implications
- Sixth Conclusion
- Implications
- Seventh Conclusion
- Implications
- Eighth Conclusion
- Implications
- Ninth Conclusion
- Implications
- Tenth Conclusion
- Implications
- Eleventh Conclusion
- Implications
- Twelfth Conclusion
- Implications
- Thirteenth Conclusion
- Implications
- Fourteenth Conclusion
- Implications
Appendix A: Glossary
Appendix B: Company Names and Addresses
List of Exhibits
- Chapter One: Executive Summary
- Table 1-1: The Size Of Cancer Therapeutic Markets In The Seven Major World Healthcare Markets: 1998-2006 (Us$ Billions)
- Figure 1-1: The Size Of Cancer Therapeutic Markets In The Seven Major World Healthcare Markets: 1998-2006
- Figure 1-2: Distribution By Segment Of Cancer Therapeutics Markets: 2000
- Chapter Three: Cancer Epidemiology
- Table 3-1: Populations Of The Major World Healthcare Markets: 1998 - 2006 (Millions)
- Figure 3-1: Trends In The Populations Of The Major World Healthcare Markets: 1998 - 2006 (Millions)
- Table 3-2: Estimated Cancer Prevalence In The Major World Healthcare Markets: 1998 - 2000 (Millions)
- Figure 3-2: Trends In The Cancer Prevalence Rates For The World's Major Healthcare Markets: 1998 - 2006 (Patients Per 100,000 Population)
- Table 3-3: Estimated Incidence (New Cases) Of Selected Cancers In The World's Major Healthcare Markets: 2000 (Thousands)
- Figure 3-3: Distribution Of Major Cancer Incidences In The Seven Major World Healthcare Markets:2000
- Chapter Four: Cancer Therapy Markets
- Figure 4-1: Growth In The Cancer Therapeutics Markets For The Seven Major World Healthcare Markets: 1998 - 2006 (Us$ Billions)
- Table 4-1: Historic And Forecast Market Size For Cancer Therapeutics In The Seven Major World Healthcare Markets: 1998 - 2006 (Us$ Billions)
- Figure 4-2: Historic And Future Growth In Antineoplastic Drug Sales In The Seven Major World Healthcare Markets: 1998 - 2006
- Figure 4-3: Historic And Future Growth In Adjunctive And Side-Effect Management Drug Sales In The Seven Major World Healthcare Markets: 1998 - 2006 (Billions)
- Table 4-2: Historic And Forecast Market Size For Cancer Therapeutics In The Seven Major World Healthcare Markets By Region: 1998 - 2006 (Us$ Billions)
- Figure 4-4: Historic And Future Growth In Regional Cancer Therapeutic Drug Sales In The Seven Major World Healthcare Markets: 1998 - 2006 (Billions)
- Chapter Five: Current Therapeutic Approaches And Technology
- Table 5-1: Therapeutic Options In The Treatment Of Cancer
- Table 5-2: Commonly Used Chemotherapeutics For Specific Cancers
- Table 5-3: Commonly Used Hormone Therapeutics For Specific Cancers
- Chapter Six: Advanced Cancer Therapeutics And The New Paradigm
- Figure 6-1: Cancer Patient Survival As A Function Of Therapeutic Mode
- Table 6-1: Emerging Cancer Therapies
- Table 6-2: Comparison Of Emerging Cancer Therapies
- Table 6-3: Emerging Cancer Therapies: Developmental Risks
- Figure 6-2: Timeline For Advanced Cancer Therapeutic Development
- Table 6-4: Estimated Peak Market Potentials For Advanced Cancer Therapeutics (Us$ Millions)
- Chapter Seven: Immunological And Vaccine Approaches
- Table 7-1: Cytokines And Growth Factors That Influence The Immune System In Cancer Patients
- Table 7-2: Immune Response-Enhancing Herbs
- Table 7-3: Active Clinical Trials Involving Cancer Immunotherapy
- Chapter Eight: Antiproliferative Approaches
- Table 8-1: Endogenous Angiogenesis Regulators
- Table 8-2: Key Angiongenesis Inhibitors In Development
- Table 8-3: Active Clinical Trials Involving Antiangiogenesis In Cancer Therapy
- Chapter Nine: Photodynamic Therapy
- Table 9-1: Photosensitizers In Application With Cancer Photodynamic Therapy
- Table 9-2: Active Clinical Trials Involving Photodynamic Therapy For Cancer
- Chapter Ten: Gene Therapy Approaches
- Table 10-1: Physical Gene Transfer Technologies
- Table 10-2: Chemically Assisted Gene Transfer Technologies
- Table 10-3: Viral Vector Gene Transfer Technologies
- Table 10-4: Active Clinical Trials Involving Genetic Therapy For Cancer
- Chapter Eleven: Cell Cycle And Apoptosis Approaches
- Table 11-1: Representative Chemotherapeutic Agents Employed On The Basis Of Cell Cycle Selectivity
- Table 11-2: Cell Cycle Regulators
- Table 11-3: Cell Cycle Regulators By Phase
AbstractThese reports analyze two dynamic areas of pharmaceutical research and development; immunotherapy and cancer therapy.
Current Developments in Immunotherapy Markets and Technology
Beyond congenital and acquired immune deficiencies immunotherapy is employed in a number of major disease areas such as hypersensitivity/allergy and cancer. The application in organ transplantation dealing with prevention of allograph rejection and transplantation sickness has long been known.
This report from MarketResearch.com examines this market and provides forecasts to 2005 for major immunotherapy products including:
- Corticosteroids
- Cyclosporin and Related Immunosuppresives
- NSAIDS
- Gamma Globulins
- Monoclonal Antibodies
- Cytokines/Lymphokines
- Immunizations and vaccines
In addition, the use of Genetic Manipulation for immunomodulation will be discussed in detail.
The report will present and detail advanced research efforts.
Commercial efforts and strategic alliances will be clearly presented for the specific companies profiled in the report.
Advances in Cancer Therapy
As we enter the 21st century, advances in the treatment of cancer will be significant and the patient will benefit in terms of quality of life. It is not unreasonable to anticipate a time when many cancer patients are managed as if they were chronically ill.
These thoughts are being shaped and driven by a variety of forces:
- A new paradigm that would make use of the patient's natural immune and control systems
- The vast array of developing knowledge in the area of cells
- New products under development based on the immune system and cell function or death
- Critical strategic alliances between researched-based pharmaceutical and biotech
This MarketResearch.com study focuses on the five key segments that will impact advanced cancer therapy:
- Immunological and vaccine approaches
- Antiproliferative approaches
- Photodynamic therapy
- Gene therapy approaches
- Cell cycle and apoptosis approaches
The study provides forecast information and examines selected dynamics and cancer statistics for the seven major world markets.
The report provides detailed company profiles which include:
- Current products
- Product pipeline
- Key strategic alliances (large and small)
- Discussions of the core technologies R&D activities
Get Full Details About This Report >>
|
